Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 11c; Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $60.76 million versus the consensus estimate of $56.85 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $375-385 million, versus the consensus of $382.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
